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ABSTRACT  
Objectives: The 2013 Diabetes Canada guidelines launched targeted dissemination tools and a 
simple assessment for vascular protection. We aimed to: (1) examine changes in the rates of 
vascular protective medications prescribed in primary care for older patients with diabetes 
associated with the launch of the 2013 guidelines, and (2) examine differences in the rates of 
vascular protective prescriptions by patient and provider characteristics.  
Research Design and Methods: The study population included patients (≥40y) from the 
Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with type 2 diabetes and at 
least one clinic visit from April 2010-December 2015. An interrupted time-series (ITS) analysis 
was used to assess the proportion of eligible patients prescribed an HMG-CoA Reductase 
Inhibitor (statin), ACE-Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), or antiplatelet 
prescription in each quarter. Proton Pump Inhibitor (PPI) prescriptions were the reference control. 
Results: A dynamic cohort was used where participants were enrolled each quarter using a pre-
specified set of conditions (range 25,985-70,693 per quarter). There were no significant changes 
in statin (p=0.43), ACEI/ARB (p=0.42), antiplatelet (p=0.39) or PPI (p=0.16) prescriptions at 
baseline (guideline intervention). After guideline publication, there was a significant change in 
slope for statins (-0.52%/quarter; standard error [SE] 0.15, p<0.05), ACEI/ARBs (-
0.38%/quarter; SE 0.13, p<0.05) and reference PPI prescriptions (-0.18%/quarter; SE 0.05, 
p<0.05).  
Conclusions: There was a decrease in prescribing trends over time that was not specific to 
vascular protective medications. More effective knowledge translation strategies are needed to 
improve vascular protection in diabetes in order for patients to receive the most effective 
interventions.  
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INTRODUCTION 
The World Health Organization (WHO) describes the 'rule of halves' whereby half of the people 
with long-term conditions are not known, half of those known are not treated and half of those 
treated are not controlled (1).  As a result of these failures patients with diabetes are at increased 
risk of developing significant morbidity and mortality related to atherosclerotic cardiovascular 
complications including coronary heart disease, stroke and peripheral vascular disease (2). The 
lifetime 10-year cardiovascular disease (CVD) risk is >20% for patients aged >40 years and 
living with diabetes (3). Effective risk factor modification with vascular protective medications, 
including statins, antihypertensive agents and antiplatelet agents is an essential component of 
diabetes management to improve both quantity and quality of life years (3,4). Clinical trial data 
show a 22-37% risk reduction in CVD for patients age >40 years on statin therapy, and a 25% 
risk reduction for patients age >55 years taking ACE inhibitors (ACEIs) (4–6). Despite evidence-
based support for these therapies, a national physician survey in 2012 estimated that 43% of 
patients with diabetes do not meet guideline-recommended LDL targets (≤2 mmol/L) and 64% 
fail to meet BP targets (<130/80 mmHg), suggesting suboptimal vascular protection management 
(7).  
 
To bridge this evidence to practice gap for vascular protection in patients with diabetes, 
dissemination tools were launched with the 2013 Diabetes Canada (previously Canadian 
Diabetes Association) evidence-based guidelines. Compared with previous (2008) guidelines, the 
2013 Diabetes Canada guidelines no longer require providers to stratify patients into different 
risk categories prior to recommending vascular protective therapy, thereby simplifying the 
assessment for vascular protection (Supplemental Table 1). Statin use is recommended for all 
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patients ≥40 years and living with diabetes; ACEIs or angiotensin receptor blockers (ARBs) are 
recommended for patients ≥55 years with diabetes. Antiplatelet medications are no longer 
recommended for routine use in the primary prevention of CVD for patients with diabetes (3). 
Diabetes Canada also expanded on their patient- and provider-directed dissemination and 
implementation strategy, which was based on the Knowledge-to-Action Cycle and included a 
variety of new dissemination tools (8). The nation-wide disemination strategy launched in April 
2013 and targeted multiple national and provincial systems-level groups (e.g. government 
agencies, non-governmental agencies, disease advocacy groups, and professional associations), 
as well as health care providers and people living with diabetes across Canada via large scale 
communications campaigns (e.g. television, radio, digital and print media) (Supplemental Table 
2) (9). Interventions including in-person lecture series, conferences, webinars, web-based 
professional and patient resources such as flowsheets, electronic point of care decision support, a 
mobile application, and Electronic Medical Record (EMR) templates were rolled out over 24 
months. An evaluation of the effectiveness of this dissemination strategy has been published 
elsewhere (9). 
 
Multiple studies examining vascular protective agents in Canada have shown an increase in 
statins and ACEIs/ARBs prescribed and used over the past two decades (10–12). Estimates from 
one Canadian province (Ontario) suggest that statin prescriptions in patients with diabetes aged 
>65 years have increased 53% from 1996-2010 and ACEI/ARB prescriptions have increased by 
22% over a 6-year period (1995-2001) (11,12).  These studies used data from provincial drug 
registries, which failed to capture non-prescription medications including antiplatelets and 
typically involved smaller geographic areas (i.e. city or provincial level data), making it difficult 
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to determine if dissemination and implementation of the Diabetes Canada guidelines achieved a 
population-level impact across Canada. Drug registry data also exclude the population of patients 
with diabetes age <65 years who may be eligible for vascular protective therapy. In addition, 
there are no studies that examined the prescription of these medications before and after the 2013 
Diabetes Canada guidelines were released and disseminated, leaving the impact of the guidelines 
unknown. 
 
Successful guideline evaluation is critical in assessing whether suggested recommendations have 
been adopted into practice at a population level. The current study used data from the Canadian 
Primary Care Sentinel Surveillance Network (CPCSSN), a pan-Canadian EMR surveillance 
system, to capture longitudinal trends in vascular protective agent prescriptions. The specific 
aims were to: (1) examine changes in the rates of vascular protective medications prescribed in 
primary care for older patients with diabetes associated with the launch of the 2013 Diabetes 
Canada Guidelines and additional dissemination efforts, and (2) examine differences in the rates 
of vascular protective medication prescriptions according to provider and patient characteristics.  
 
RESEARCH DESIGN AND METHODS 
Study Design and Population 
We used a retrospective cohort design and followed the STROBE guidelines (13).  We included 
patients living with diabetes whose data were in the CPCSSN database from April 2010 to 
December 2015. Diabetes was defined according to the CPCSSN validated case definition 
(Supplemental Table 3) (14). The study cohort was dynamic, and patients were enrolled 
quarterly when the following three temporal conditions were met: [1] Onset of diabetes recorded 
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in the EMR prior to or during each quarter of interest, [2] First patient visit recorded within a 
given quarter or any quarter preceding it, [3] Patient met eligibility criteria for the medication 
being analyzed defined as per the 2013 Diabetes Canada guideline criteria: patients age ≥40 
years for statins; age ≥55 for ACEI/ARBs. For antiplatelet agents, patients age ≥40 years with no 
cardiovascular event were included as guideline changes suggest that these medications should 
no longer be used for primary prevention in this group. Priorities set were based on well-
accepted guideline recommendations and framed such that in our defined cohorts, those 
prescribed the agent are “controlled”, and those not prescribed the agent are “uncontrolled”. 
Achievement of LDL targets (≤2 mmol/L) and blood pressure (BP) targets (<130/80 mmHg) 
were assessed in patients in the following age categories: age ≥40 years for LDL, age ≥55 years 
for BP. We employed a censoring point whereby patients were removed from the cohort using 
the last encounter date if they had not seen their family doctor as indicated by an encounter in the 
EMR in the last two years. The study was approved by the University of Toronto’s Research 
Ethics Board (REB#33127).  
 
CPCSSN Database 
CPCSSN, established in 2008, is an EMR-based information system designed for chronic disease 
surveillance. Every three months, EMR data from primary care practices in 10 practice-based 
research networks (PBRNs) across Canada are extracted, cleaned and merged into a single 
database housed at the Centre for Advanced Computing at Queen’s University in Kingston, 
Ontario (15). Contributing PBRNs are located in Alberta (2), British Columbia (1), Manitoba (1), 
Newfoundland and Labrador (1), Nova Scotia (1), Ontario (3) and Quebec (1). The network is 
composed of over 1,100 family physicians contributing data for more than 1,500,000 patients. 
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Information contained in the database includes network and provider identifiers, de-identified 
patient demographic information, date and type of each patient’s encounters, patient health 
conditions, risk factors, referrals, laboratory investigations, procedures and medications (15).  
CPCSSN captures all medications recorded in the EMR, including medications prescribed by 
primary care providers or specialists, and those purchased over the counter. 
 
Data Collection and Processing 
Data from January 1st 2010 to December 31st 2015 were used for this project. The project data 
included patient demographic variables (year and month of birth, sex, and neighbourhood level 
socioeconomic status (SES) indicators derived from residential postal codes), physical 
measurements (height, weight, body mass index (BMI), systolic BP, diastolic BP), diabetes-
related laboratory records (i.e. total cholesterol, LDL, HDL, triglycerides, urine 
albumin/creatinine ratio), comorbidities/risk factors (i.e. hypertension, CVD, dyslipidemia, 
microalbuminuria, smoking history), all medications prescribed to patients (i.e. lipid lowering 
agents, ACEIs, ARBs, antiplatelets, and PPIs as a reference control), and provider/site 
characteristics (i.e. province of site, rurality of site) for each quarter of interest, and CPCSSN 
patient and provider data table (containing information on hierarchical relationship between 
patient, care provider, site and network). Year of medical school graduation for providers was 
collected from the University of Toronto PBRN (UTOPIAN) network only due to limited 
availability at other PBRNs. 
 
All medications in CPCSSN database were coded using Anatomical Therapeutic Chemical 
(ATC) codes; these codes were used to identify the relevant medications for this project (16). 
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Long-term conditions were identified using CPCSSN validated algorithms where available (i.e. 
diabetes mellitus and hypertension; Supplemental Table 3). For the rest of conditions we used 
coded and free text diagnosis data from CPCSSN health conditions table; this table populates 
data from Cumulative Patient Profile (CPP) (14). CVD was defined according to guideline and 
antiplatelet indications to include ICD-9 codes for coronary heart disease (410-414), 
cerebrovascular disease (430-438), and peripheral vascular disease (440-445) (17). Dyslipidemia 
was defined using appropriate medication history, coded and free text diagnosis data, and 
included patients on lipid-lowering therapy or with LDL >2.0 mmol/L. Albuminuria was defined 
according to Diabetes Canada guidelines, whereby a urine albumin creatinine ratio <2 mg/mmol 
was normal, 2-20 mg/mmol was considered microalbuminuria, and >20 mg/mmol was 
macroalbuminuria (18). SES, was measured in accordance with the Canadian Institute for Health 
Information method of deriving neighbourhood-level deprivation indices on a quintile scale for 
each patient (19). Rurality was defined according to postal code whereby a second letter of “0” 
was considered rural and a second letter “1 to 9” considered urban (20). In accordance with 
recommendations of the WHO and Health Canada, BMI was classified as underweight (<18.5 
kg/m2), normal weight (18.5–24.99 kg/m2), overweight (25–29.99 kg/m2), obese class I (30–
34.99 kg/m2), obese class II (35–39.99 kg/m2) and class III (≥40 kg/m2) categories (21).  
 
Analysis 
This study used an interrupted time-series (ITS) design. For the primary analysis, the proportion 
of eligible patients who had prescriptions for statins, ACEI/ARBs and antiplatelets in each 
quarter was computed using a longitudinal data analysis (22). Quarterly intervals were chosen to 
introduce less fluctuation in the time-series curve compared to a monthly approach (23). If 
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patients had multiple visits within a quarter, the most recent record was used for all variables 
studied. A total of 8 quarters before, 1 quarter during, and 9 quarters after the intervention were 
analyzed.  Patients were deemed to be prescribed a statin, ACEI/ARB or antiplatelet agent if they 
had any prescription record in the four preceding quarters and one quarter after each quarter of 
interest (lag4, lead1) (Figure 2). This approach was used to account for variation in refill 
protocols and prescription procedures among family physicians (i.e. some provide a prescription 
every three months, others provide multiple repeats) (24). Having 4 quarters before and 1 after 
each quarter of interest would provide a sufficient timeframe to capture prescriptions given on a 
yearly basis. We also examined other approaches, including (lag0, lead0), (lag1, lead1), (lag2, 
lead2), (lag3, lead3), (lag4, lead4), and (lag4, lead1). We found that prescription rates for the 
latter three approaches were very similar, further justifying our selection of the lag4, lead1 
approach.  
 
The Diabetes Canada guidelines and dissemination strategy launched April 2013, was considered 
the intervention point (2013Q2). A segmented regression model was used to assess baseline 
trend/slope, the level change immediately after intervention, and the trend/gradual change (25). 
We also measured the prescription rates of statin, ACEI/ARB and antiplatelets using a cross-
sectional study design, which deemed a patient to be using the medication if they had at least one 
prescription during the entire study period (2010Q1-2015Q4). This approach serves as a 
sensitivity analysis for the lag4, lead1 approach and allowed us to test for subgroup differences 
in the proportion prescribed statin, ACEI/ARB and antiplatelets. 
 
Secondary analyses included the proportion of eligible patients attaining LDL (≤2.0 mmol/L) or 
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BP targets (<130/80 mmHg). A carryover approach was implemented: each patient’s most recent 
measurement was used in the following quarters until a new measurement was recorded in the 
EMR. A segmented regression model was used to assess the baseline trend/slope, level change 
and trend/gradual change for secondary outcomes (i.e. eligible patients attaining LDL or BP 
targets).  
 
Results were stratified by patient characteristics (age, sex, BMI, SES), presence of risk 
factors/comorbidities (smoking, CVD, hypertension, dyslipidemia, albuminuria) and provider 
characteristics (province of care, rurality). We assessed the statistical significance across patient, 
provider and geographical characteristics for prescription rates for statins, ACEI/ARBs and 
antiplatelet agents using chi-square test (adjusted for multiple hypothesis testing). We used the 
method of false discovery rate to control for inflated Type I error rates in multiple hypothesis 
testing procedure (26). PPI prescriptions were used as a reference to control for confounding 
factors. Using modified hypothesis testing, we compared the temporal difference in prescription 
rates of PPIs to all three vascular protective medications (e.g. statin 2011Q2-2015Q3 vs PPI 
2011Q2-2015Q3), and considered statistical significance at p<0.05. The analyses were 
conducted using SAS v.9.4 (27). 
 
RESULTS 
Primary Outcomes 
The total number of patients enrolled in each dynamic cohort is outlined in Table 1. Quarterly 
cohort size ranged from 23,016-70,693 patients (Supplemental Table 4).. Variation in population 
size was attributed to increasing recruitment of practices into the CPCSSN database over time. 
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Results of the ITS analysis are presented in Table 2 and graphically in Figure 1. There were no 
significant changes in the rate of statin, ACEI/ARB, antiplatelet or PPI prescriptions prior to the 
release of the 2013 guidelines. After guideline publication, there was a significant change in 
slope for statins (-0.52%/quarter; standard error [SE] 0.15, p<0.05) and ACEI/ARBs (-
0.38%/quarter; SE 0.13, p<0.05) prescribed. A significant change in slope was also seen for PPI 
prescriptions (-0.18%/quarter; SE 0.05, p<0.05). The change in slope was not significant for 
antiplatelets. The absolute difference in the rates of statin, ACEI/ARB, or antiplatelet 
prescriptions from the start (2011 Q2) to the end (2015 Q4) of the study period were significantly 
less than that of the PPI reference control (p<0.0001).  
 
Geographic Characteristics 
Prescription rates in eligible patients were significantly higher in urban compared to rural 
practices for statins, ACEI/ARBs, and antiplatelets across the study period (Table 2(a)-(c)). Chi-
square test revealed significant differences in prescriptions rates between provinces for statins 
(p<0.001), ACEI/ARBs (p<0.001), and antiplatelets (p<0.001). Statin and ACEI/ARB 
prescription rates were highest in the province of Quebec (74.2% for statins; 55.9% for 
ACEI/ARBs) and the Maritimes (64.8% for stains; 50.5% for ACEI/ARBs) and lowest in 
Alberta (45.1% for statins; 39.5% ACEI/ARBs) and British Columbia (35.2% for statins; 41.5% 
ACEI/ARBs). 
 
Provider Characteristics 
There were no significant differences between MD graduation groups for statin (p=0.152) or 
ACEI/ARB (p=0.18) prescriptions in the UTOPIAN population (Table 2 (a)-(c)). However, there 
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were significant differences between MD graduation groups for antiplatelet prescriptions 
(p<0.001). Antiplatelet prescription rates were 20.9% for MD graduation years of 1965-1979, 
15.3% for 1980-1994, and 18.3% for ≥1995.   
 
Patient Demographics and Risk Factors 
Prescription rates according to patient characteristics are seen in Table 2(a)-(c). There were no 
significant gender-based differences in prescription rates for statins (p=0.99), ACEI/ARBs 
(p=0.71) or antiplatelet agents (p=0.15). Patients with hypertension had significantly higher 
statin (p<0.001), ACEI/ARB (p<0.001), and antiplatelet (p<0.001) prescription rates compared 
to patients without hypertension. Patients with CVD also had higher statin (p<0.001) and 
ACEI/ARB (p<0.001) prescription rates compared to patients without CVD. Patients without 
dyslipidemia had significantly lower rates of statin prescription (p<0.001), ACEI/ARB 
prescriptions (p<0.001), and antiplatelet prescriptions (p<0.001) compared to those with 
dyslipidemia. Significant differences were detected for age groups, SES quintiles, smoking status, 
hypertension, dyslipidemia, and albuminuria for all three vascular protective medications 
(p<0.05). Significant differences between BMI groups were seen with respect to ACEI/ARB 
prescriptions (p<0.001).  
 
Secondary Outcomes 
LDL and BP Targets 
Across the study period, LDL and BP targets were achieved by 47-57% and 61-66% of patients, 
respectively (Figures 1(b)-(c)). The release of the 2013 guidelines did not significantly impact 
the proportion of patients achieving BP targets as there were no significant changes in this 
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proportion before, during or after guideline release (Table 1). The release of the guidelines did 
not impact the proportion of patients achieving LDL targets, as there were no significant changes 
in this proportion during or after guideline release.  
 
CONCLUSIONS 
The results of this large study suggest that dissemination of the 2013 Diabetes Canada guidelines 
was not associated with any further improvements in physician prescribing behaviour as 
measured by EMR prescription estimates for primary vascular protection in patients age ≥40 
years with diabetes. While there was no change in prescriptions at the intervention point, a small 
but statistically significant decrease in slope after guideline publication was observed with statins 
and ACEI/ARBs, as well as the reference control. A negative change in slope (improved 
guideline adherence) was also observed with antiplatelets, however this change was not 
significant. There were no significant changes with respect to LDL and BP targets at or after 
guideline intervention. Overall prescription rates were influenced by factors including rurality, 
province, and patient age and SES. While statistically significant changes were seen across 
patient/provider characteristics, these do not necessarily represent clinical significance given the 
large sample size.  
 
Our time-series analysis revealed a negative change in slope for statins, ACEI/ARBs and PPIs. 
Due to a lack of sufficient variation in the time-series curves shown in Figure 1(a)-(c), the reader 
is cautioned that this statistical inference can be affected by minuscule change in prescription 
rates during any quarter pre- and post-guideline implementation (28). This decrease was also 
seen with the PPI comparator suggesting that external factors cannot be excluded. It is possible 
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that there was no actual improvement in vascular protective prescribing after release of the 2013 
guidelines. The CPCSSN population also involves a dynamic cohort, so a change in composition 
of patients, physicians or sites included in the database in each quarter could also influence 
prescription rates. Entry to the dynamic cohort was random, and there would be no reason to 
suspect that patients with diabetes from practices joining CPCSSN later would be more likely to 
have lower prescribing rates.  We also did not observe any remarkable shifts with respect to 
composition of site locations, but did observe an increase in patients age 40-49 from 5.89% to 
9.15% across the study period. Patients in this age category had lower statin and ACEI/ARB 
prescription rates, and thus an increase in the proportion of these patients may have contributed 
to the measurable decrease seen in prescribing rates over time. It is also possible that an 
emerging focus on resource stewardship in medical education and practice, influenced physicians 
to prescribe more cautiously, decreasing prescription rates over time (29).  
 
Our prescription estimates are lower than those from 2003 and 2008 Diabetes Canada guideline 
evaluations (7,30). These studies used physician self-reported survey data, subject to selection 
bias as physicians willing to participate may be those that prescribe in accordance with guideline 
recommendations. A validation study is currently ongoing to compare our results with data from 
the Institute for Clinical and Evaluative Sciences, (ICES), which encompasses publicly funded 
administrative health data for the Ontario population eligible for universal health coverage (31). 
Preliminary results from this study confirm no improvement in statin, ACEI, and ARB 
prescriptions at or after guideline intervention (p>0.05). Statin prescription estimates were 
similar (62-65%) to those in the current study (52-56%) and increased rates may be attributed to 
the older population cohort included in ICES (age≥65). 
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We observed better guideline adherence in urban areas and provinces including Quebec, Ontario, 
and the Maritimes. It is possible that dissemination outreach strategies were less effective for 
removed locations including rural areas and provinces such as Northwest Territories, Alberta and 
British Colombia. Increased distance from health care access leading to reduced frequency of 
physician visits may inhibit rural physicians from adhering to guidelines (32). Rural physicians 
report increased patient resistance to medical or preventative care as a barrier to guideline 
adherence (32). We also observed lower prescription rates among patients from lower SES 
brackets, which is consistent with low SES cohorts being less likely to receive guideline-
recommended diabetes care (33).  
 
National survey data from primary care providers across Canada highlights significant gaps in 
knowledge and behaviour change constructs for vascular protection (9). While awareness of the 
2013 Diabetes Canada vascular protective guidelines was 71% among survey respondents, only 
22% had correct knowledge of guideline content for vascular protection upon questioning, and 
only 21% reported adhering to guideline recommendations (9). It remains possible that despite 
ongoing dissemination efforts, prescription rates may have reached a ceiling in terms of any 
further improvements in uptake. 
 
Limitations of this study should be acknowledged. First, the CPCSSN cohort involves a 
convenience sample of patients, providers, and practices, which limits the generalizability of 
findings. Second, results must be interpreted carefully, as prescription estimates may not 
correspond with actual medication usage. Third, the CPCSSN validated case definition for 
16 
 
diabetes differed from the 2013 Diabetes Canada guidelines definition. The CPCSSN definition 
includes both type 1 and type 2 diabetes, with an HbA1c ≥7% or fasting glucose ≥7 mmol/L, 
while Diabetes Canada includes an HbA1C ≥6.5% or fasting glucose ≥7 mmol/L. We suspect 
that CPCSSN was unable to capture some patients who would otherwise be considered as having 
diabetes by the Diabetes Canada guidelines, potentially overestimating the rates of statin and 
ACEI/ARB prescriptions, as usage of these medications is associated with higher HbA1c levels 
(34,35). However, we suspect that this number would have been small as patients can be 
captured by other diabetes criteria according to the CPCSSN case definition (14). Fourth, a lack 
of a validated case definition for CVD, microalbuminuria and dyslipidemia in CPCSSN may 
reduce the specificity and sensitivity of multiple estimates. Finally, ITS analyses cannot infer 
cause-effect relationships, as external factors are not accounted for. An analysis of PPIs showed 
similar trends as the vascular protective prescriptions under investigation, suggesting that the 
potential for confounding effects cannot be excluded.  
  
There are limitations unique to using practice-based EMRs, whereby accuracy and completeness 
can vary across different systems, providers and sites, in turn affecting the validity of the study 
(36). It is possible that a full record of patient medications including those requiring manual 
input (non-prescription, specialist prescriptions), are not recorded in the EMR by all providers. 
Accordingly, data from non-prescription medications as a group are typically less accurate than 
prescription estimates (37). Antiplatelet agents carry significant bleeding risk, and we suspect 
that they would be more likely to be recorded in the EMR than other non-prescription 
medications with lower risk profiles. There is,also no reason to expect differences in the 
completeness of data pre- and post-guideline implementation.  
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Despite these limitations, this study captured trends in vascular protective medication 
prescriptions in a large sample of Canadian primary care patients with diabetes. Previous studies 
have primarily used provincial data, and are limited in their generalizability at a national level. 
Using longitudinal data enabled assessment of trends over time, and allowed for effective 
guideline evaluation at a population level. EMR data allowed for a more valid assessment of 
prescription rates, as self-reported data often overestimates medication adherence behaviour (38). 
EMR data also allowed us to capture the rates of non-prescription medications including 
antiplatelet agents, and data across greater age ranges (i.e. age <65), which are often unavailable 
with drug registry data.  
 
We carried out statistical inference using an ITS design, which is considered a stronger research 
design than the traditional before and after longitudinal design, and remains the recommended 
quasi-experiment design when a randomized control trial is not feasible at the community level 
(39,40). The total number of patients prescribed medications per quarter were aggregated into a 
single population-level proportion and therefore results correspond to an intervention effect at 
the population level rather than the individual level. ITS has also been mainly used in conditions 
applicable to our study: a macro-level intervention (nation-wide guideline dissemination 
strategy), a uni-dimensional outcome (prescription rates for vascular protective agents), and 
including a large population of patients with diabetes in primary care (25). 
 
This study highlights a persistent gap in the management of vascular protection among patients 
with diabetes. Qualitative assessments are needed to assess the collective experience of 
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physicians and elicit factors not captured in our quantitative design (i.e. registries which capture 
information about why a physician did not prescribe a guideline-recommended treatment).  
Further dissemination efforts should be targeted at groups with lower adherence rates including 
physicians from rural areas, and those treating patients with lower SES. They may also involve 
EMR-based prompts to serve as reminders for providers. It is possible that a ceiling level of 
vascular protective medication uptake has been achieved, however it is necessary to explore 
other reasons for guideline non-adherence and revise dissemination strategies accordingly before 
arriving at this conclusion. 
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FIGURE LEGENDS 
Figure 1a. Proportion of eligible patients prescribed vascular protective medications in Canada, 
quarterly from 2011-2015 
 
Diamond = statin; circle = ACEI/ARB; square = PPI (reference); triangle = antiplatelet 
 
*Solid line indicates the intervention point of guideline publication and dissemination (2013 Q2). 
 
 
 
Figure 1b. Proportion of eligible patients achieving recommended LDL and BP targets in 
Canada, quarterly from 2011-2015 
 
Circle = LDL; square = BP 
 
*Solid line indicates the intervention point of guideline publication and dissemination (2013 Q2). 
 
 
 
 
Figure 2. Lag4, lead1 approach for sample quarter (2013 Q2). 
 
*2013 Q2 represents the quarter of interest. As illustrated, data from 4 lag quarters (2012 Q2 – 
2013 Q1) and 1 lead quarter (2013 Q3) will be included in the analysis for 2013 Q2.
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Table 1. Patient, provider and geographical characteristics for statin, ACEI/ARB and antiplatelet 
prescriptions among patients with Type 2 diabetes 
 
 
 Statin medication ACE/ARBi medication Antiplatelets medication 
 N Percent (%) P-value N Percent (%) P-value N Percent (%) P-value 
Age (years)          
40-49 4084 56.1% 0.0006 - - - 814 13.4% 0.001 
50-59 9766 58.6%  3023 39.8% <.0001 2125 15.3%  
60-69 13448 58.7%  11142 48.7%  2982 15.6%  
70-79 10769 58.3%  8910 48.2%  2377 15.4%  
80+ 8589 59.2%  7076 48.7%  1781 14.7%  
BMI (kg/cm2)          
< 18.5 227 59.1% 0.33 163 51.1% 0.004 48 15.1% 0.34 
18.5-24.9 4162 60.5%  2877 50.1%  902 15.8%  
25-29.9 9455 60.4%  6431 49.3%  1947 14.8%  
30-34.9 8734 59.9%  5575 47.8%  1839 15.1%  
35-39.9 4857 59.3%  2915 47.5%  987 14.4%  
>=40 3992 59.0%  2196 47.1%  821 14.6%  
Missing 15229 55.5%  9994 45.6%  3535 15.5%  
Gender          
Female 22147 58.4% 0.99 14365 47.6% 0.71 4723 14.9% 0.15 
Male 24505 58.4%  15786 47.4%  5355 15.3%  
Missing 4 44.4%  . .  1 14.3%  
SES quintiles          
1 (highest) 3958 59.4% <.0001 2574 47.3% 0.001 847 15.2% 0.001 
2 5071 61.6%  3233 49.5%  989 14.6%  
3 4577 61.1%  2919 48.4%  948 15.1%  
4 3957 58.2%  2603 48.1%  833 14.7%  
5 (lowest) 4134 56.0%  2595 45.7%  778 12.7%  
Missing 24959 57.6%  16227 47.2%  5684 15.7%  
Smoking 
status 
         
Current Smoker 4280 59.5% <.0001 2460 48.3% 0.015 926 15.5% 0.008 
Non Smoker 8065 58.0%  5356 49.0%  1614 14.0%  
Past smoker 9798 63.4%  6500 50.5%  1956 15.1%  
Missing 24513 56.6%  15835 45.8%  5583 15.4%  
Hypertension          
No 16551 50.0% <.0001 8160 31.0% <.0001 3481 11.7% <.0001 
Yes 30105 64.4%  21991 59.2%  6598 17.8%  
Dyslipidemia          
No 8461 41.3% <.0001 6485 39.3% <.0001 2240 13.2% <.0001 
Yes 38195 64.3%  23666 50.3%  7839 15.8%  
Albuminuria          
micro 11190 69.5% <.0001 7623 60.0% <.0001 2645 20.5% <.0001 
Normal 13861 63.2%  8438 48.7%  2898 15.4%  
macro 3372 73.1%  2493 68.2%  838 24.7%  
Missing 18233 49.0%  11597 38.9%  3698 11.7%  
CVD          
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No 36395 54.6% <.0001 23456 44.2% <.0001 10079 15.1% N/A 
Yes 10261 77.8%  6695 64.1%     
Rurality          
rural 8895 53.9% <.0001 5984 44.5% <.0001 1976 14.5% 0.001 
urban 33049 61.1%  21137 49.2%  7094 15.7%  
Missing 4712 50.9%  3030 42.9%  1009 12.8%  
Province          
AB 5804 45.1% <.0001 4022 39.5% <.0001 1076 9.9% <.0001 
BC 385 35.2%  366 41.5%  85 9.5%  
MB 9044 59.2%  5758 48.6%  1977 15.8%  
MP 1636 64.8%  1048 50.5%  540 26.3%  
NL 1941 54.0%  1421 48.6%  494 16.8%  
NW 722 56.9%  439 55.4%  200 19.2%  
ON 26194 62.4%  16483 48.9%  5519 15.6%  
QC 930 74.2%  614 55.9%  188 17.9%  
Graduation 
year 
         
1965-1979 1871 70.6% 0.15 1241 57.0% 0.18 472 20.9% <.0001 
1980-1994 5769 67.8%  3764 54.9%  1094 15.3%  
>=1995 5872 69.2%  3688 56.1%  1323 18.3%  
Non-UTOPIAN 33144 55.0%  21458 44.8%  7190 14.4%  
Total number 
of patients 
prescribed 
medication  
46656 58.4%  30151 47.5%  10079 15.1%  
 Total number 
of patients 
enrolled in 
dynamic 
cohort over 
study period 
79880 100%  63494 100%  66,683 100%  
 
 
 
Table 2. Interrupted time-series regression analysis of vascular protective medication prescribing 
rates 
 
 
  Estimate Standard 
Error 
P value 
Statin     
 Intercept B0 50.97 0.95 <0.0001 
 Pre-intervention trend 
B1 
0.33 0.10 0.0072 
 Level change  0.35 0.43 0.4280 
 Trend change -0.52 0.15 0.0045 
ACEI/ 
ARB 
    
 Intercept B0 41.66 0.85 <0.0001 
 Pre-intervention trend 
B1 
0.14 0.09 0.1691 
 Level change 0.37 0.45 0.4218 
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 Trend change -0.38 0.13 0.0127 
Antiplatelet     
 Intercept B0 9.75 0.44 <0.0001 
 Pre-intervention trend 
B1 
0.13 0.05 0.3918 
 Level change -0.26 0.30 0.3918 
 Trend change -0.06 0.06 0.3129 
PPI     
 Intercept B0 18.92 0.36 <0.0001 
 Pre-intervention trend 
B1 
0.39 0.04 <0.0001 
 Level change 0.31 0.21 0.1586 
 Trend change -0.18 0.05 0.0044 
*Pre-intervention trend (before guideline intervention), Level change (at guideline intervention), Trend 
change (difference in slope before/after guideline intervention) 
 
 
 
 
